Regulatory News

Filters

Date / Time Source Ticker Company Sector Market Cap Announcement
07 Jan 2020 09:48 EQS 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
23 Apr 2019 11:27 EQS 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28 Feb 2019 12:05 EQS 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25 Jan 2019 15:18 EQS 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10 Jan 2019 15:37 EQS 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10 Dec 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14 Nov 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
17 Aug 2018 09:15 EQS 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea Pharmaceutica AG (BSLN-CH): Cresemba shines in H1/2018 results
14 Aug 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
13 Aug 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports on first Cresemba® approval in MENA region
09 Aug 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
19 Jul 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America
16 Jul 2018 10:35 EQS 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
26 Jun 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
05 Jun 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting
15 May 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
04 May 2018 10:44 EQS 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea Pharmaceutica AG (BSLN-CH): Derazantinib deal adds third oncology asset
27 Apr 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management
20 Apr 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
18 Apr 2018 17:06 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders
18 Apr 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
17 Apr 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
09 Apr 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
19 Mar 2018 11:10 EQS 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea Pharmaceutica AG (BSLN-CH): Reaping the rewards of an intense BD period
06 Mar 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
01 Mar 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea names Adesh Kaul as new member of its Management Committee
27 Feb 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports significantly improved financial results in 2017
23 Feb 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
21 Feb 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
10 Jan 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
03 Jan 2018 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
21 Dec 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
01 Dec 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
02 Nov 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports on commercial progress of antifungal Cresemba® in Europe
31 Oct 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
23 Oct 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
11 Oct 2017 13:17 EQS 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
28 Sep 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
12 Sep 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
10 Aug 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
20 Jul 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
14 Jun 2017 18:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
14 Jun 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
13 Jun 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
12 Jun 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
06 Jun 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
02 Jun 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea names new member of its Extended Management Committee
27 Apr 2017 17:32 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
21 Apr 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
06 Apr 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
27 Feb 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
20 Feb 2017 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports solid 2016 results and expects to double product sales in 2017
29 Dec 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea names new member of its Extended Management Committee
02 Dec 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
15 Nov 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea's antifungal Cresemba® (isavuconazole) launched in France
20 Sep 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
15 Sep 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
13 Sep 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
06 Sep 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553
17 Aug 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region
15 Aug 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets
27 Jun 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy
09 Jun 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
21 Apr 2016 17:30 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
20 Apr 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
15 Apr 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
15 Mar 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea issues agenda for Annual General Meeting of Shareholders
09 Mar 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
04 Mar 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
03 Mar 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
29 Feb 2016 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
21 Jan 2016 20:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
29 Dec 2015 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
28 Dec 2015 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea provides clinical program updates
18 Dec 2015 17:42 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Final allocations of Basilea CHF 200 million senior convertible bonds
09 Dec 2015 17:36 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea successfully places CHF 200 million senior convertible bonds
09 Dec 2015 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea launches a senior convertible bond issue
05 Nov 2015 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
23 Oct 2015 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces that European Commission maintained isavuconazole's orphan drug status
16 Oct 2015 19:43 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces filing of registration statement for a proposed offering in the United States
16 Oct 2015 15:48 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
15 Oct 2015 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
12 Oct 2015 06:15 GNW 0QNA:LON Basilea Pharmaceutica AG Health 615.3m Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections
Date / Time Source Company % Chg
07 Jan 2020 09:48 EQS Basilea Pharmaceutica AG 0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
23 Apr 2019 11:27 EQS Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28 Feb 2019 12:05 EQS Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25 Jan 2019 15:18 EQS Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10 Jan 2019 15:37 EQS Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10 Dec 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14 Nov 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
17 Aug 2018 09:15 EQS Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba shines in H1/2018 results
14 Aug 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
13 Aug 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports on first Cresemba® approval in MENA region
09 Aug 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
19 Jul 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America
16 Jul 2018 10:35 EQS Basilea Pharmaceutica AG 0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
26 Jun 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
05 Jun 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting
15 May 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
04 May 2018 10:44 EQS Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib deal adds third oncology asset
27 Apr 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management
20 Apr 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
18 Apr 2018 17:06 GNW Basilea Pharmaceutica AG 0.00%
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders
18 Apr 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
17 Apr 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
09 Apr 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
19 Mar 2018 11:10 EQS Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Reaping the rewards of an intense BD period
06 Mar 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
01 Mar 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea names Adesh Kaul as new member of its Management Committee
27 Feb 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports significantly improved financial results in 2017
23 Feb 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
21 Feb 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
10 Jan 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
03 Jan 2018 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
21 Dec 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
01 Dec 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
02 Nov 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports on commercial progress of antifungal Cresemba® in Europe
31 Oct 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
23 Oct 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
11 Oct 2017 13:17 EQS Basilea Pharmaceutica AG 0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
28 Sep 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
12 Sep 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
10 Aug 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
20 Jul 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
14 Jun 2017 18:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
14 Jun 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
13 Jun 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
12 Jun 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
06 Jun 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
02 Jun 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea names new member of its Extended Management Committee
27 Apr 2017 17:32 GNW Basilea Pharmaceutica AG 0.00%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
21 Apr 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
06 Apr 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
27 Feb 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
20 Feb 2017 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports solid 2016 results and expects to double product sales in 2017
29 Dec 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea names new member of its Extended Management Committee
02 Dec 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
15 Nov 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea's antifungal Cresemba® (isavuconazole) launched in France
20 Sep 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
15 Sep 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
13 Sep 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
06 Sep 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553
17 Aug 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region
15 Aug 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets
27 Jun 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy
09 Jun 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
21 Apr 2016 17:30 GNW Basilea Pharmaceutica AG 0.00%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
20 Apr 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
15 Apr 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
15 Mar 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea issues agenda for Annual General Meeting of Shareholders
09 Mar 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
04 Mar 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
03 Mar 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
29 Feb 2016 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
21 Jan 2016 20:15 GNW Basilea Pharmaceutica AG 0.00%
GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
29 Dec 2015 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
28 Dec 2015 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea provides clinical program updates
18 Dec 2015 17:42 GNW Basilea Pharmaceutica AG 0.00%
Final allocations of Basilea CHF 200 million senior convertible bonds
09 Dec 2015 17:36 GNW Basilea Pharmaceutica AG 0.00%
Basilea successfully places CHF 200 million senior convertible bonds
09 Dec 2015 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea launches a senior convertible bond issue
05 Nov 2015 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
23 Oct 2015 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces that European Commission maintained isavuconazole's orphan drug status
16 Oct 2015 19:43 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces filing of registration statement for a proposed offering in the United States
16 Oct 2015 15:48 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
15 Oct 2015 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
12 Oct 2015 06:15 GNW Basilea Pharmaceutica AG 0.00%
Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections
Date / Time Company % Chg
07 Jan 2020 09:48 Basilea Pharmaceutica AG 0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
23 Apr 2019 11:27 Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28 Feb 2019 12:05 Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25 Jan 2019 15:18 Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10 Jan 2019 15:37 Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10 Dec 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14 Nov 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
17 Aug 2018 09:15 Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba shines in H1/2018 results
14 Aug 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
13 Aug 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports on first Cresemba® approval in MENA region
09 Aug 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
19 Jul 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America
16 Jul 2018 10:35 Basilea Pharmaceutica AG 0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
26 Jun 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
05 Jun 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting
15 May 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
04 May 2018 10:44 Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib deal adds third oncology asset
27 Apr 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management
20 Apr 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
18 Apr 2018 17:06 Basilea Pharmaceutica AG 0.00%
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders
18 Apr 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
17 Apr 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
09 Apr 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
19 Mar 2018 11:10 Basilea Pharmaceutica AG 0.00%
Basilea Pharmaceutica AG (BSLN-CH): Reaping the rewards of an intense BD period
06 Mar 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
01 Mar 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea names Adesh Kaul as new member of its Management Committee
27 Feb 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports significantly improved financial results in 2017
23 Feb 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
21 Feb 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
10 Jan 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
03 Jan 2018 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
21 Dec 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
01 Dec 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
02 Nov 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports on commercial progress of antifungal Cresemba® in Europe
31 Oct 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
23 Oct 2017 06:15 Basilea Pharmaceutica AG 0.00%
Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
11 Oct 2017 13:17 Basilea Pharmaceutica AG 0.00%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
28 Sep 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
12 Sep 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
10 Aug 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
20 Jul 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
14 Jun 2017 18:15 Basilea Pharmaceutica AG 0.00%
Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
14 Jun 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
13 Jun 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
12 Jun 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
06 Jun 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
02 Jun 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea names new member of its Extended Management Committee
27 Apr 2017 17:32 Basilea Pharmaceutica AG 0.00%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
21 Apr 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
06 Apr 2017 06:15 Basilea Pharmaceutica AG 0.00%
Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
27 Feb 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
20 Feb 2017 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports solid 2016 results and expects to double product sales in 2017
29 Dec 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea names new member of its Extended Management Committee
02 Dec 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
15 Nov 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea's antifungal Cresemba® (isavuconazole) launched in France
20 Sep 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
15 Sep 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
13 Sep 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
06 Sep 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553
17 Aug 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region
15 Aug 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets
27 Jun 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy
09 Jun 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
21 Apr 2016 17:30 Basilea Pharmaceutica AG 0.00%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
20 Apr 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
15 Apr 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
15 Mar 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea issues agenda for Annual General Meeting of Shareholders
09 Mar 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
04 Mar 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
03 Mar 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
29 Feb 2016 06:15 Basilea Pharmaceutica AG 0.00%
Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
21 Jan 2016 20:15 Basilea Pharmaceutica AG 0.00%
GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
29 Dec 2015 06:15 Basilea Pharmaceutica AG 0.00%
Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
28 Dec 2015 06:15 Basilea Pharmaceutica AG 0.00%
Basilea provides clinical program updates
18 Dec 2015 17:42 Basilea Pharmaceutica AG 0.00%
Final allocations of Basilea CHF 200 million senior convertible bonds
09 Dec 2015 17:36 Basilea Pharmaceutica AG 0.00%
Basilea successfully places CHF 200 million senior convertible bonds
09 Dec 2015 06:15 Basilea Pharmaceutica AG 0.00%
Basilea launches a senior convertible bond issue
05 Nov 2015 06:15 Basilea Pharmaceutica AG 0.00%
Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
23 Oct 2015 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces that European Commission maintained isavuconazole's orphan drug status
16 Oct 2015 19:43 Basilea Pharmaceutica AG 0.00%
Basilea announces filing of registration statement for a proposed offering in the United States
16 Oct 2015 15:48 Basilea Pharmaceutica AG 0.00%
Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
15 Oct 2015 06:15 Basilea Pharmaceutica AG 0.00%
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
12 Oct 2015 06:15 Basilea Pharmaceutica AG 0.00%
Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections